Roth Capital analyst Debjit Chattopadhyay was out pounding the table on Uniqure NV (NASDAQ:QURE) Friday, reiterating a Buy rating and price target of $38 price target, which represents a potential upside of 29% from where the stock is currently trading.

Chattopadhyay wrote, “During 2H15 we anticipate FIX liver expression data from the first cohort of Hemophilia B patients currently being enrolled, and one-year follow up data from LSD (Sanfilippo B, not in our model). Sanfilippo program, if successful, should allow for breakthrough therapy designation, and a rapid path to commercialization, which translates into a two-year+ head start over competition. Additionally, Parkinson’s program (not currently valued) has begun dosing its second cohort, and CV-collaboration with BMY is on track for 2016 clinical debut.”

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of 33.9% and a 73.1% success rate. Chattopadhyay has a 5.5% average return when recommending QURE, and is ranked #10 out of 3623 analysts.

All the 6 analysts polled by TipRanks rate uniQure N.V. stock a Buy. With a return potential of 44.6%, the stock’s consensus target price stands at $42.60.